Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms.
The expected effectiveness of protease inhibitors was assessed according to the Agence Nationale de Recherches sur le SIDA (ANRS), Rega and Stanford 2007 resistance algorithms in 93 and 87 antiretroviral therapy-naive patients, respectively, infected with B and non-B subtype viruses. Either B or non-B subtypes were considered fully susceptible to protease inhibitors, except to tipranavir/ritonavir, for which the 2007 ANRS algorithm scored non-B subtypes as naturally resistant when this algorithm was extended to these subtypes.
Champenois
Karen
K
CRESGE-LEM-CNRS, Lille, France. k.champenois@free.fr
Bocket
Laurence
L
Deuffic-Burban
Sylvie
S
Cotte
Laurent
L
André
Patrice
P
Choisy
Philippe
P
Yazdanpanah
Yazdan
Y
D000465:Algorithms; D019380:Anti-HIV Agents / Q000494:pharmacology; D024882:Drug Resistance, Viral; D005602:France; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000145:classification / Q000187:drug effects*; D006801:Humans; D011725:Pyridines / Q000494:pharmacology; D011753:Pyrones / Q000494:pharmacology; D019438:Ritonavir / Q000494:pharmacology; D013449:Sulfonamides
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir